Tandem Diabetes Care宣布，其Control-Iq+自动胰岛素输送技术正式获得美国食品药品监督管理局（FDA）批准，可用于1型糖尿病患者的妊娠期管理。这项突破性进展为孕期糖尿病管理提供了更精准、自动化的解决方案。Control-Iq+技术通过智能算法实时调整胰岛素输注量，帮助维持血糖稳定。此次获批标志着该技术在特殊人群应用领域取得重要进展，有望提升妊娠期糖尿病患者的治疗体验与安全性。
Tandem Diabetes Care宣布，其Control-Iq+自动胰岛素输送技术正式获得美国食品药品监督管理局（FDA）批准，可用于1型糖尿病患者的妊娠期管理。这项突破性进展为孕期糖尿病管理提供了更精准、自动化的解决方案。Control-Iq+技术通过智能算法实时调整胰岛素输注量，帮助维持血糖稳定。此次获批标志着该技术在特殊人群应用领域取得重要进展，有望提升妊娠期糖尿病患者的治疗体验与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.